Reumatologia clinica最新文献

{"title":"Anti-Mi-2-positive amyopathic dermatomyositis unveiled by a V-sign","authors":"Sadettin Uslu","doi":"10.1016/j.reumae.2026.502163","DOIUrl":"10.1016/j.reumae.2026.502163","url":null,"abstract":"","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 6","pages":"Article 502163"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148321148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antinuclear antibody detection beyond anti-dsDNA and anti-ENA: New insights from intact HEp-2 nucleus ELISA","authors":"Faruk Dişli,&nbsp;Sedat Yıldız","doi":"10.1016/j.reumae.2026.502165","DOIUrl":"10.1016/j.reumae.2026.502165","url":null,"abstract":"<div><h3>Background</h3><div>Intact HEp-2 nucleus-based ELISA tests are occasionally preferred for antinuclear antibody (ANA) screening, although their correlation with clinically relevant autoantibodies such as anti-dsDNA and anti-ENA remains unclear. This study analyzed the correlation between HEp-2 nucleus-based ELISA and anti-dsDNA and anti-ENA tests in a large sample to provide analytical insight into their relationship.</div></div><div><h3>Material and methods</h3><div>A total of 900 serum samples were included in the study (mean age: 39.7 years; 481 females and 419 males). Anti-dsDNA, anti-ENA, and intact HEp-2 nucleus-based ELISA tests were performed in all samples using validated ELISA methods. Correlation analyses between test results were performed using Spearman's rank correlation coefficient due to non-normal data distribution.</div></div><div><h3>Results</h3><div>HEp-2 ELISA showed a moderate correlation with anti-dsDNA (<em>r</em> <!-->=<!--> <!-->0.431, <em>p</em> <!-->&lt;<!--> <!-->0.001) and a stronger correlation with anti-ENA (<em>r</em> <!-->=<!--> <!-->0.625, <em>p</em> <!-->&lt;<!--> <!-->0.001). Among the 431 individuals who tested positive in at least one of the three assays, 96 were positive for all three. Additionally, 41 individuals were positive for both anti-dsDNA and HEp-2, and 44 for both anti-ENA and HEp-2. Isolated positivity was observed in 112 individuals for anti-dsDNA, 48 for anti-ENA, and 54 for HEp-2. This distribution reflects both overlapping and distinct patterns of antibody detection among the tests.</div></div><div><h3>Conclusions</h3><div>HEp-2 nucleus-based ELISA demonstrated analytical concordance with both anti-dsDNA and anti-ENA assays. Moreover, its ability to detect distinct autoantibody reactivities not identified by conventional methods suggests its value as a complementary tool in comprehensive ANA screening.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 6","pages":"Article 502165"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148321127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with the perception of body image in patients with psoriatic disease","authors":"Kevin R. García-Fong,&nbsp;Iris P. García-Herrera,&nbsp;Silvia Méndez-Flores,&nbsp;Irazú Contreras-Yáñez,&nbsp;Guillermo A. Guaracha-Basañez","doi":"10.1016/j.reumae.2026.502155","DOIUrl":"10.1016/j.reumae.2026.502155","url":null,"abstract":"<div><h3>Background</h3><div>Patients with psoriatic disease (PsD), including psoriasis (Pso) and psoriatic arthritis (PsA), often experience challenges related to body image due to the visible nature of their lesions and their impact on quality of life.</div></div><div><h3>Objective</h3><div>To describe body image perception (BIP) and explore the factors associated with it in patients with PsD.</div></div><div><h3>Methods</h3><div>A cross-sectional study involving 91 patients with PsD was conducted. Clinical evaluations included disease activity scores, patient-reported outcomes, and validated questionnaires assessing body image, quality of life, fatigue, anxiety, and depression. Multivariate analyses were performed to determine associations.</div></div><div><h3>Results</h3><div>Higher disease activity, as measured by PASI and DAPSA, was associated with poorer BIP. Multivariate analyses identified functional impairment, fatigue, and psychological factors as key determinants of BIP.</div></div><div><h3>Conclusions</h3><div>In this Mexican PsD cohort, poorer BIP was independently associated with functional impairment, fatigue, anxiety/depression, and nail involvement, underscoring the need for multidisciplinary strategies that address both physical and psychological domains.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 6","pages":"Article 502155"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148321182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two curious cases of muscle weakness secondary to sarcoidosis: Sarcoid myopathy, a rare entity","authors":"Sabela Castañeda Pérez,&nbsp;Nuria Vázquez Temprano,&nbsp;Ana Fernández Argüeso,&nbsp;Sara Astor Molero,&nbsp;Carmen Malvarez Martín-Aragón,&nbsp;Julia Diéguez Paz,&nbsp;Hadrián Pernas Pardavila,&nbsp;Eide Diana Alves Pereira","doi":"10.1016/j.reumae.2026.502158","DOIUrl":"10.1016/j.reumae.2026.502158","url":null,"abstract":"","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 6","pages":"Article 502158"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148321360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causes of biologic therapy withdrawal in patients with rheumatic diseases: An observational cohort study from Southeastern Mexico","authors":"Angel Alejandro Castillo Ortiz,&nbsp;Aaron Alejandro Barrera Rodriguez","doi":"10.1016/j.reumae.2026.502171","DOIUrl":"10.1016/j.reumae.2026.502171","url":null,"abstract":"<div><h3>Background and objective</h3><div>Biologic therapy withdrawal in inflammatory rheumatic diseases is a frequent event with direct consequences on disease control, safety, and care costs. Real-world data from southeastern Mexico remain scarce. The objective of this study was to describe the causes of biologic treatment withdrawal and to explore factors associated with drug survival in patients attending a referral rheumatology clinic in southeastern Mexico.</div></div><div><h3>Patients and methods</h3><div>Observational, retrospective cohort study. The unit of analysis was the biologic treatment episode. After data cleaning, 583 episodes from 426 unique patients were included (mean 1.37 episodes/patient). Kaplan-Meier curves were constructed for treatment line and biologic class; comparisons used the log-rank test (presented descriptively given potential within-patient correlation). A multivariable Cox proportional hazards model was fitted with a cluster-robust sandwich variance estimator grouped by patient. Significance level: <em>p</em> &lt; 0.05.</div></div><div><h3>Results</h3><div>84.0% of patients were female; median age 51 years (IQR 41–58). Rheumatoid arthritis accounted for 76.7% of episodes and anti-TNF agents for 87.3% of biologic use. A total of 175 withdrawals (30.0%) were recorded. Among episodes with a documented reason, inefficacy was the most frequent cause (<em>n</em> = 134; 84.3%), followed by adverse events (<em>n</em> = 24; 15.1%) and non-medical causes (<em>n</em> = 1; 0.6%). No significant difference in drug survival by treatment line was observed (log-rank <em>p</em> = 0.40). Descriptive differences were observed across biologic classes (log-rank <em>p</em> &lt; 0.001). In the adjusted Cox model, the anti-IL-6 class was associated with lower withdrawal risk (HR 0.14; 95% CI 0.06–0.37; <em>p</em> &lt; 0.001) versus anti-TNF.</div></div><div><h3>Discussion and conclusions</h3><div>In this single-center cohort from southeastern Mexico, inefficacy was the most commonly identified medical cause of biologic withdrawal. Descriptive differences in drug survival were observed across biologic classes, with the most consistent signal in the anti-IL-6 class. These findings are hypothesis-generating and should be confirmed in larger, multicenter registries with more complete covariate adjustment.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 6","pages":"Article 502171"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148261277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consultation time as a determinant of quality of care and patient safety in rheumatology","authors":"Gabriel Horta-Baas","doi":"10.1016/j.reumae.2026.502153","DOIUrl":"10.1016/j.reumae.2026.502153","url":null,"abstract":"","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 6","pages":"Article 502153"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148261298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term stability of autoantibody-based serological profiles in systemic lupus erythematosus","authors":"Leyre Riancho-Zarrabeitia,&nbsp;Oihane Ibarguengoitia Barrena,&nbsp;Montserrat Santos-Gomez,&nbsp;Elena Aurrecoechea,&nbsp;Isla Morante,&nbsp;Javier Rueda-Gotor,&nbsp;Mario Agudo-Bilbao,&nbsp;Ignacio Villa,&nbsp;Marcos López-Hoyos,&nbsp;Víctor Martínez-Taboada","doi":"10.1016/j.reumae.2026.502172","DOIUrl":"10.1016/j.reumae.2026.502172","url":null,"abstract":"<div><h3>Background/Objectives</h3><div>Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease marked by diverse autoantibodies. While serological clusters have been associated with distinct clinical phenotypes, most existing studies rely on single time-point assessments and implicitly assume long-term stability of autoantibody profiles. Whether these profiles remain stable over prolonged follow-up has not been systematically evaluated. This study aimed to evaluate the longitudinal serological changes in SLE patients.</div></div><div><h3>Methods</h3><div>A retrospective study was conducted on 82 SLE patients at a hospital in northern Spain. Clinical data and immunological profiles were collected at baseline and during follow-up. Autoantibodies analyzed included ANA, anti-dsDNA, anti-Sm, anti-RNP, anti-SSa (Ro)/SSb (La), and antiphospholipid antibodies (aCL, aB2GPI, LA). Patients were classified into four serological clusters based on baseline antibody profiles.</div></div><div><h3>Results</h3><div>The cohort was predominantly female (90%), with a mean follow-up of ∼14 years. ANA was positive in nearly all patients. Regarding ANA specificities, anti SSa (Ro) antibodies were the most frequently founded in 28 patients (34%) followed by anti-dsDNA in 19 (23%), anti RNP in 11 (13%), anti SSb (La) in 8 (10%) and lastly anti Sm in 7 (9%). Only 9 of 66 patients (14%) changed serological clusters during follow-up, and most changes did not alter baseline cluster assignment. Most seroconversions involved anti-RNP, anti-Ro, and anti-Sm. Among aPLs, persistent changes occurred in 5 patients, and transient changes in 12. Overall, 86% of patients maintained stable serological profiles.</div></div><div><h3>Conclusions</h3><div>These findings demonstrate that autoantibody-based serological profiles in SLE are highly stable over long-term follow-up, supporting their validity as enduring disease classifiers with potential prognostic and therapeutic implications.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 6","pages":"Article 502172"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148321357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic and procedural profile of private Rheumatology in Spain","authors":"Lola Fernández-Fuente-Bursón,&nbsp;Susana Gerechter Fernández,&nbsp;Beatriz Yoldi Muñoz,&nbsp;Javier del Pino-Montes,&nbsp;on behalf of the SERPA group researchers","doi":"10.1016/j.reumae.2026.502127","DOIUrl":"10.1016/j.reumae.2026.502127","url":null,"abstract":"","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 5","pages":"Article 502127"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148159706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vertebral “bone-within-bone” appearance after childhood bisphosphonate therapy in a patient with osteogenesis imperfecta","authors":"Javier Manzaneque Sánchez,&nbsp;Laura Álvarez Ortiz,&nbsp;Piedad León Rubio,&nbsp;Ricardo Gil Vélez","doi":"10.1016/j.reumae.2026.502162","DOIUrl":"10.1016/j.reumae.2026.502162","url":null,"abstract":"","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 5","pages":"Article 502162"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148159758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smoking, inflammation and joint health: A toxicological perspective in knee osteoarthritis","authors":"Javier Fernández-Torres ,&nbsp;Gabriela Angélica Martínez-Nava ,&nbsp;Ashley Astrid Martínez-Villarreal ,&nbsp;Yessica Zamudio-Cuevas ,&nbsp;Carmen Guadalupe Hernández-Valencia ,&nbsp;Carlos Martín Torre-Morales ,&nbsp;Bertha Vargas-Sandoval ,&nbsp;Víctor Ilizaliturri-Sánchez ,&nbsp;Rolando Espinosa-Morales ,&nbsp;Jesús Fabián Cervantes-Meneses ,&nbsp;Ambar López-Macay ,&nbsp;Karina Martínez-Flores","doi":"10.1016/j.reumae.2026.502157","DOIUrl":"10.1016/j.reumae.2026.502157","url":null,"abstract":"<div><div>The impact of smoking on osteoarthritis (OA) remains controversial. This study aimed to evaluate the effect of smoking, adjusted for body mass index (BMI) and medication use, on systemic and joint inflammation in patients with knee OA. Peripheral blood (PB), synovial fluid (SF), and histological samples were analyzed from patients stratified by smoking status, pain level (VAS), tobacco index (TI), and use of DMARDs, NSAIDs, and analgesics. IL-1β, IL-6, and TNF-α levels were measured by ELISA. Histological evaluation of extracellular matrix (ECM) used Alcian blue and Safranin O staining. Statistical analyses included ANOVA, Dunn's test, Spearman's and Kendall's correlations, and linear regression adjusted for age and BMI.</div></div><div><h3>Results</h3><div>Smoking OA patients (OA-S) showed significantly higher plasma TNF-α levels compared to non-smokers (OA-NS) (<em>P</em> <!-->&lt;<!--> <!-->0.01), and reduced proteoglycan content (47.15%) compared to former smokers (OA-ExS) (72.74%) (<em>P</em> <!-->&lt;<!--> <!-->0.01). A moderate negative correlation was observed between SF IL-1β and proteoglycans in OA-ExS. In OA-S, plasma TNF-α strongly correlated with SF IL-6 (<em>P</em> <!-->&lt;<!--> <!-->0.05). Plasma TNF-α correlated with pain in OA-S, while IL-1β did so in OA-ExS (<em>P</em> <!-->&lt;<!--> <!-->0.01). BMI positively correlated with SF IL-6 in OA-S (<em>P</em> <!-->&lt;<!--> <!-->0.01). Analgesic and NSAID use were associated with increased plasma TNF-α in OA-S and OA-ExS. Regression models showed that smoking was significantly associated with elevated plasma TNF-α and SF IL-6 levels, independent of BMI and age.</div></div><div><h3>Conclusion</h3><div>Smoking, combined with excess weight and medication use, may enhance chronic inflammation and contribute to increased severity of knee OA.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"22 5","pages":"Article 502157"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148267565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}